Advancing
a New Front
in the War against Cancer

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects


PV-10

An Investigational Drug for Cancer

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

IN THE MEDIA

February 17, 2015

Melanoma News Today Covers Recent Paper on Importance of Intralesional Melanoma Treatment

Melanoma News Today covered a paper recently published in Current Opinion in Oncology entitled "Intralesional therapy for advanced melanoma: promise and limitation".

February 13, 2015

Late Melanoma Patients Will Need Several Lines of Therapy, Intralesional Treatment Promising Says New Paper

A recent paper in Current Opinion in Oncology states that despite advances in melanoma treatment, many patients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma will need several lines of therapy.

February 10, 2015

BIO CEO Presentation Available

Slides from Provectus' presentation at the BIO CEO and Investor Conference will be available at 3 pm EDT on February 10, 2015.

February 10, 2015

Provectus Biopharmaceuticals Concludes FDA Meeting for PV-10 Phase 3

A BioMedReports article reports on the recently completed FDA meeting for PV-10 phase 3.

January 29, 2015

Kate's Foundation Covers Grant of PV-10 Synthesis Patent in China

Kate's Foundation has posted news, first appearing on inPharmaTechnologist.com, that the Chinese government has granted Provectus a patent protecting a method of making the active pharmaceutical ingredient (API) in PV-10.

January 29, 2015

Provectus receives Chinese patent application allowance for melanoma drug candidate

Healio reports that Provectus has received allowance from the Chinese Patent Office for an application to protect its synthetic process for producing the small molecule rose bengal, the active pharmaceutical ingredient (API) in PV-10, a melanoma drug candidate.

January 28, 2015

Society for Melanoma Research and American Heart Association Scientific Sessions

In a P&T Community article reporting on the Society for Melanoma Research annual meeting, Dr. Merrick Ross discusses how PV-10's mechanism of action may be synergistic with ipilimumab.

January 27, 2015

China patent gives Provectus green light to find partner for melanoma candidate

in-Pharma Technologist reports that the patent covering synthesis of PV-10 API, recently granted by the Chinese government, enables licensing deals between Provectus and Chinese partners.

January 26, 2015

Dermwire: Novel Synthesis Patent Application Allowed by Chinese Patent Office

Dermwire covers news that the Chinese Patent Office has allowed Provectus' patent application covering the synthesis of PV-10.

January 22, 2015

Video: Plans for a Phase 3 Study of PV-10 in Melanoma

In a video appearing on P&T Community, Dr. Robert Andtbacka of the University of Utah discusses plans for a phase 3 trial involving PV-10 in patients with stage 3b and 3c melanoma who have failed or were not candidates for immunotherapy and patients who are BRAF-negative and who currently don’t have good treatment options.

January 20, 2015

The WallStreet Transcript Interviews Peter Culpepper, CFO, COO

Peter Culpepper, CFO and COO of Provectus, was recently interviewed by The WallStreet Transcript. In the interview, Mr. Culpepper discusses clinical development status, including a Phase 3 trial of PV-10 for melanoma and Phase 1b/2 trials of PV-10 for liver cancer and PV-10 combined with immune checkpoint blockade agents for melanoma. Mr. Culpepper also answers questions of clinical study time frames, funding, and potential partners.

January 12, 2015

India West Announces AAPI Global Clinical Trials Network

India West reports on the launch of the American Association of Physicians of Indian Origin's launch of the Global Clinical Trials Network. Provectus has committed to being the inaugural member of the Global Clinical Trial Network.

January 9, 2015

In-Pharma Technologist Reports Addition of Pfizer Director to Provectus' Strategic Advisory Board

In-Pharma Technologist reports that Deanna Angello, a Director of Commercial Strategy and New Business Planning within the Global Established Pharma business at Pfizer has joined Provectus' Strategic Advisory Board.

January 8, 2015

WallStreet Scope Reports on Recent Provectus Performance

The Mid-Day Changers section of WallStreet Scope for January 8, 2015 reports Provectus as a stock to watch.

January 8, 2015

Property Mentor Group Announces Provectus' Participation at the Annual AAPI Conference

Property Mentor Group, in the Top News section for January 8, 2015, reports on Provectus' participation at the Annual American Association of Physicians of Indian Origin Conference in Orlando.

January 8, 2015

Global clinical trials network launched during AAPI summit

An article appearing in the India Post announces the launch of the AAPI – Global Clinical Trials Network, a new initiative of American Association of Physicians of Indian Origin.

January 7, 2015

Provectus to Be Inaugural Member of the AAPI Global Clinical Trial Network

An article titled "AAPI - Global Clinical Trials Network launched during Global Healthcare Summit 2015 in Mumbai" appearing on NRI News announces the launch of the Global Clinical Trials Network, a new initiative of the American Association of Physicians of Indian Origin (AAPI). The new initiative was launched on January 4th, 2015 during the Global Health Care Summit in Mumbai in India. Provectus has committed to be the inaugural member of the Global Clinical Trial network. AAPI is looking forward to creating a large network of Pharmaceutical companies to make this initiative a great success.

January 6, 2015

Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study

An article appearing on Dermwire covers news of Provectus' upcoming meeting with the US FDA to review certain operational aspects of the protocol for a planned phase 3 clinical trial of intralesional PV-10 as a treatment for melanoma. No date for this meeting has been agreed upon as yet.

December 30, 2014

Promising Strategy for Advanced Melanoma: Intralesional Therapies Plus Systemic Immunotherapies

In an article appearing in Cancer Watch, cancer researchers discuss the promising strategy of combining intralesional drugs such as PV-10, that stimulate an immune response by killing tumor cells in a manner whereby intact antigens are expressed, with drugs such as ipilimumab and pembrolizumab that act as immune checkpoint inhibitors.

December 19, 2014

Decision-Plus Interviews Provectus CFO and COO Peter Culpepper

In a video interview appearing on decisionplus.com, Peter Culpepper, CFO and COO of Provectus Biopharmaceuticals, discusses the current status of PV-10 development, regulatory events, compassionate care, and global market strategy.

more...

PRESS RELEASES

February 24, 2015

Provectus Biopharmaceuticals Will Hold Its 2014 Year-End Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, March 12, 2015

Provectus announced today that it will hold its year-end quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, March 12, 2015.

February 18, 2015

Provectus Biopharmaceuticals Will Present at 8th Annual European Life Science CEO Forum & Exhibition

Provectus announced today that it will present at the 8th Annual European Life Science CEO Forum & Exhibition. Peter Culpepper, CFO and COO, will present on March 3, 2015, at 3:15 pm local time.

February 10, 2015

Provectus Biopharmaceuticals Will Present at 17th Annual BIO CEO And Investor Conference Tuesday, February 10, 2015

Provectus announced today that it will present at the 17th Annual BIO CEO and Investor Conference on Tuesday, February 10,2015.

February 9, 2015

Provectus Biopharmaceuticals Met with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study

Provectus announced today that it has held a Type C meeting with the U.S. Food and Drug Administration to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma.

February 6, 2015

Provectus Biopharmaceutical's PV-10 Featured in Article by Sanjiv Agarwala in Current Opinion in Oncology

Provectus announced today that an article, entitled "Intralesional therapy for advanced melanoma: promise and limitation," authored by Sanjiv S. Agarwala, MD, has been published in the March issue of Current Opinion in Oncology, now available online.

January 29, 2015

Provectus Biopharmaceuticals Begins Recruitment for Phase 2 Mechanism of Action Clinical Trial Of PH-10 For Psoriasis

Provectus announced today that it has opened recruitment for its phase 2 mechanism of action trial of PH-10 for the treatment of mild to moderate psoriasis.

January 26, 2015

Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Office

Provectus announced today that it has received notification of allowance from the Chinese Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the Company's lead oncology drug candidate.

December 23, 2014

Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Markers of Psoriasis Now Available Online

Provectus announced today that the protocol for its phase 2 study of the mechanism of action of PH-10 in psoriasis is now available on ClinicalTrials.gov, Identifier NCT02322086:

December 22, 2014

Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment

Provectus announced today that it will be meeting with the U.S. Food and Drug Administration (the "FDA") to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma. No date for this meeting has been agreed upon as yet.

December 17, 2014

Provectus Biopharmaceuticals To Sponsor American Association of Physicians of Indian Origin

Provectus announced today that it has agreed to sponsor the activities of the American Association of Physicians of Indian Origin (AAPI). In addition, Provectus will participate at AAPI's 2015 Global Healthcare Summit in Mumbai, India, running from January 2-4, 2015, as well as at the Annual AAPI Conference in Orlando, Florida, running from June 17-21, 2015.

November 14, 2014

Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd

Provectus announced today that it has agreed to extend the term of its existing Memorandum of Understanding (MOU) with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group to May 16, 2015. The MOU remains in effect and unchanged other than this extension of the term.

November 13, 2014

Provectus Biopharmaceuticals' Protocol for Phase 3 Study Of PV-10 As Treatment for Melanoma Now Available Online

Provectus announced today that the protocol for its phase 3 study of PV-10 as a treatment for melanoma is now available on: http://clinicaltrials.gov/ct2/show/study/NCT02288897?term=provectus&rank=6.

November 10, 2014

Provectus Biopharmaceuticals PV-10 Data Presented at SITC 29TH Annual Meeting

Provectus announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of cancer was featured in a poster presentation at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting on Saturday, November 8, 2014.

November 6, 2014

Provectus Biopharmaceuticals, Inc. Reports Third Quarter Results

Provectus today announced financial results for the third quarter of 2014.

November 6, 2014

Provectus Biopharmaceuticals Submits PV-10 Phase 3 Melanoma Protocol to FDA

Provectus announced today that it has submitted its phase 3 protocol for evaluation of PV-10 for treatment of locally advanced cutaneous melanoma to the FDA. The FDA is expected to review the submission and comment on the proposed study population, clinical endpoints, and statistical analyses within 30 to 45 days. Provectus believes details of the protocol will be available publicly on www.clinicaltrials.gov within the next few days.

November 6, 2014

Provectus Biopharmaceuticals Announces Abstract Available on Intralesional PV-10 and Co-inhibitory Blockade Data for SITC 29th Annual Meeting

Provectus announced today that the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," to be presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting is now available at http://www.immunotherapyofcancer.org/content/2/S3/P120.

November 6, 2014

Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call Today at 4 PM Eastern Standard Time

Provectus will host its quarterly conference call today, Thursday, November 6, 2014 at 4:00 PM EST.

October 31, 2014

Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014

Provectus will host a quarterly conference call to update the market in general and shareholders in particular about developments at the Company. The call is scheduled for Thursday, November 6, 2014 at 4:00 PM EST.

October 28, 2014

Provectus' Intralesional PV-10 Clinical Data Published in the Annals of Surgical Oncology

Provectus announced today that data on its investigational new drug PV-10, obtained in clinical trial PV-10-MM-02 ( ClinicalTrials.gov Identifier NCT00521053), has been published by the Annals of Surgical Oncology (ASO).

October 16, 2014

Provectus' Intralesional PV-10 Clinical Data to Be Presented to the 2014 International Congress of the Society for Melanoma Research

Provectus announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.

more...